Information Provided By:
Fly News Breaks for February 15, 2017
ALKS
Feb 15, 2017 | 15:06 EDT
The future remains uncertain for ALKS 5461, Alkermes' potential treatment for major depressive disorder, Cantor Fitzgerald analyst William Tanner tells investors in a post-earnings research note. The analyst is most interested in ALKS 8700 for treating multiple sclerosis, with the anticipation of a New Drug Application filing in 2018. Tanner believes pipeline development successes will be needed for Alkermes shares to be valued "meaningfully higher" than current levels. The analyst keeps a Neutral rating on the stock with a $51 price target.
News For ALKS From the Last 2 Days
ALKS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.